 |
7 Companies | 6 Products |
|
|
6 Products | |
29 Diseases | |
11 Trials |  |
763 News |  |
| «12...1314151617181920212223...134135» |
- | Journal: Ischemic Preconditioning Provides Neuroprotection by Inhibiting NLRP3 Inflammasome Activation and Cell Pyroptosis. (Pubmed Central) - Jun 28, 2023
In addition, confocal immunofluorescence staining of Annexin V-mCherry and SYTOX green was inhibited by IPC. These findings suggest a more enhanced link between IPC and inflammatory signature and cell death, highlighting that the NLRP3 inflammasome may act as a promising target for the prevention and treatment of ischemic stroke.
- | ADS032 / Adiso Therap
Journal: A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases. (Pubmed Central) - Jun 26, 2023
Critically, ADS032 protected mice from lethal influenza A virus challenge, displayed increased survival and reduced pulmonary inflammation. ADS032 is the first described dual inflammasome inhibitor and a potential therapeutic to treat both NLRP1- and NLRP3-associated inflammatory diseases and also constitutes a novel tool that allows examination of the role of NLRP1 in human disease.
- | Journal: Regulatory functional role of NLRP3 inflammasome during mycoplasma hyopneumoniae infection in swine. (Pubmed Central) - Jun 23, 2023
The impact of the NLRP3 inhibitor, MCC950 on NLRP3 and pro-inflammatory cytokines in M. hyopneumoniae-infected swine was examined to investigate the relationship between the NLRP3 inflammasome and M. hyopneumoniae infection. Taken together, our findings provide strong evidence that the NLRP3 inflammasome plays a critical regulatory functional role in M. hyopneumoniae infection in swine.
- | doxycycline / Generic mfg.
Journal: Doxycycline inhibits NLRP3 inflammasome activation by blocking the NLRP3-NEK7 interaction and MAPK/NF-?B signaling in human gingival fibroblasts. (Pubmed Central) - Jun 22, 2023
Taken together, our findings provide strong evidence that the NLRP3 inflammasome plays a critical regulatory functional role in M. hyopneumoniae infection in swine. No abstract available
- | Bay11-7082 / InvivoGen
Journal, Metastases: Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). (Pubmed Central) - Jun 22, 2023
Additionally, BAY-117082 treatment modulated the epithelial-mesenchymal transition (EMT) process in tongue tissue as well as in metastatic organs such as lymph node, lung, and spleen, also reducing the expression of matrix metalloproteinases (MMPs), particularly MMP2 and MMP9, markers of cell invasion and migration. In conclusion, the obtained data demonstrated that BAY-117082 at doses of 2.5 mg/kg and 5 mg/kg were able to reduce the tongue tumor area as well as the degree of metastasis in lymph node, lung, and spleen tissues through the NLRP3 inflammasome pathway inhibition.
- | Preclinical, Journal: Celastrol relieves myocardial infarction-induced cardiac fibrosis by inhibiting NLRP3 inflammasomes in rats. (Pubmed Central) - Jun 21, 2023
In post-MI rats, Celastrol, a naturally occurring active ingredient, was able to reduce myocardial fibrosis and improve cardiac function, according to our study. These effects may result from inhibiting the NLRP3 inflammasome and attenuating the early inflammatory storm after MI, suggesting that Celastrol may be useful in treating acute MI.
- | Journal: Panaxynol ameliorates cardiac ischemia/reperfusion injury by suppressing NLRP3-induced pyroptosis and apoptosis via HMGB1/TLR4/NF-?B axis. (Pubmed Central) - Jun 21, 2023
These effects may result from inhibiting the NLRP3 inflammasome and attenuating the early inflammatory storm after MI, suggesting that Celastrol may be useful in treating acute MI. To sum up, our results demonstrate that PNN exhibits a cardioprotective effect by modulating heart IRI-induced apoptosis and pyroptosis via HMGB1/TLR4/NF-?B pathway, thereby inhibiting NLRP3 inflammasome stimulation.
- || RRx-001 / EpicentRx
P1 data, Journal: A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma. (Pubmed Central) - Jun 21, 2023
P1
The overall response rate was 18.8% (3 PR out of 16) and the disease control rate was 68.8% (3 PR, 8 SD out of 16). The addition of RRx-001 to TMZ and RT and to TMZ during maintenance was safe and well-tolerated and deserves further study.
- | Journal: LSD1 silencing inhibits the proliferation, migration, invasion, and epithelial-to-mesenchymal transition of hypopharyngeal cancer cells by inducing autophagy and pyroptosis. (Pubmed Central) - Jun 20, 2023
Importantly, 3-MA or MCC950 addition obviously reversed the inhibitory effects of LSD1 silencing on the proliferation, migration, invasion, and EMT of hypopharyngeal cancer cells. To sum up, LSD1 silencing could restrain the progression of hypopharyngeal cancer cells by inducing autophagy and pyroptosis.
- | Journal: Hepatocyte NLRP3 interacts with PKC? to drive hepatic insulin resistance and steatosis. (Pubmed Central) - Jun 20, 2023
via NLRP3 induction for metabolic diseases and establishes the YY1-NLRP3-PKC? axis as a potential therapeutic target for NAFLD.
- | Preclinical, Journal: Paeonia lactiflora Pall. Polysaccharide alleviates depression in CUMS mice by inhibiting the NLRP3/ASC/Caspase-1 signaling pathway and affecting the composition of their intestinal flora. (Pubmed Central) - Jun 19, 2023
axis as a potential therapeutic target for NAFLD. PLP modulates depression-related intestinal ecological dysregulation, increases species richness, and inhibits inflammatory factors levels and NLRP3 inflammasome activation to reduce colonic mucosal and neurons damage, thereby improving depression-like behavior and neurotransmitter release in CUMS mice.
- | Journal: Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation. (Pubmed Central) - Jun 19, 2023
Mechanistically, in post-ischemic hearts, IFN200 reduced IRI-dependent NLRP3 activation, inflammation, and oxidative stress. These results highlight the potential of the novel NLRP3 inhibitor, INF200, and its ability to reverse the unfavorable cardio-metabolic dysfunction associated with obesity.
- | Journal: Tanshinone IIA mediates protection from diabetes kidney disease by inhibiting oxidative stress induced pyroptosis. (Pubmed Central) - Jun 19, 2023
Hyperglycemia could induce pyroptosis in renal glomerular endothelial cells. However, Tan IIA could delay the progression of DKD by inhibiting pyroptosis by regulating the Txnip/NLRP3 inflammasome.
- | LY294002 / Eli Lilly
Journal: Rosavidin protects against PM2.5-induced lung toxicity via inhibition of NLRP3 inflammasome-mediated pyroptosis by activating the PI3K/AKT pathway. (Pubmed Central) - Jun 19, 2023
Notably, those protective effects of Ro were not observed after pretreatment with a combination of Ro with nigericin or LY294002. These results indicate that Ro mitigates PM2.5-caused lung toxicity by inhibiting NLRP3 inflammasome-mediated pyroptosis through activation of the PI3K/AKT signaling pathway.
- | Journal: Microglial NLRP3 inflammasome activation mediates diabetes-induced depression-like behavior via triggering neuroinflammation. (Pubmed Central) - Jun 19, 2023
The activation of NLRP3 inflammasome, probably mainly in hippocampal microglia, mediates the development of depression-like behaviors in STZ-induced diabetic mice. Targeting the microglial inflammasome is a feasible strategy for the treatment of diabetes-related depression.
- | Journal: Oxidative stress initiates RIPK3/MLKL-mediated corneal epithelial necroptosis and NLRP3 inflammasome signaling during fungal keratitis. (Pubmed Central) - Jun 19, 2023
Taking these findings together, we demonstrated that overproduction of ROS in fungal keratitis leads to significant necroptosis in the corneal epithelium. Furthermore, the necroptotic stimuli-mediated NLRP3 inflammasome serves as a driving force in host defense against fungal infection.
- | Preclinical, Journal: Baicalin Ameliorates Lung Injury in Rats by Inhibiting NLRP3 Inflammasome Activation via NF-[Formula: see text]B Signaling Pathway. (Pubmed Central) - Jun 19, 2023
Furthermore, we found that the NF-[Formula: see text]B pathway, a canonical pro-inflammatory pathway, was also blocked after treatment with baicalin in HS-evoked rats, as indicated by the decreased expression of p65 and p65 phosphorylation in the lung tissues. In summary, we infer that baicalin may exert a protective role in HS-induced lung injury by suppressing the activation of NLRP3 inflammasome via the NF-[Formula: see text]B pathway.
- | Journal: Emodin alleviates testicular ischemia-reperfusion injury through the inhibition of NLRP3-mediated pyroptosis. (Pubmed Central) - Jun 19, 2023
Inhibitory effects of emodin on pyroptosis were attributed to the inhibition of NLRP3 inflammasomes. Thus, emodin could be an alternative treatment for testicular IRI.
- || Review, Journal: Anticancer mechanisms on pyroptosis induced by Oridonin: New potential targeted therapeutic strategies. (Pubmed Central) - Jun 17, 2023
These studies concludes that Ori has extensive anti-cancer effects that are related to its potential regulatory function on pyroptosis. The paper summarizes several potential ways in which Ori participates in the regulation of pyroptosis, providing a reference for further study on the relationship between Ori, pyroptosis, and cancer.
- Cdactin-O (CBM-588) / Osel, Miyarisan
Clostridium butyricum alleviates DSS-induced colitis mice by inhibiting NLRP3 inflammasome activation () - Jun 16, 2023 - Abstract #IDDF2023IDDF_183;
Methods Fourty-eight 6-8 week old C57BL/6 wild-type mice (WT) and matched NLRP3 knockout mice (KO) were randomly divided into six groups, and Clostridium butyricum MIYAIRI 588 was used to treat colitis mice...In the KO group, significant relief of symptoms in the DSS group, but no significant difference between the DSS group and CBM group. Conclusions CBM alleviates DSS-induced colitis by inhibiting NLRP3 inflammation activation, which may be another potential mechanism of action in the treatment of IBD.
- | chloroquine phosphate / Generic mfg.
Preclinical, Journal: Chloroquine inhibits NLRP3 inflammasomes activation and alleviates renal fibrosis in mouse model of hyperuricemic nephropathy with aggravation by a high-fat-diet. (Pubmed Central) - Jun 16, 2023
levels in HN mice. These findings suggest that CQ inhibits the activation of NLRP3 inflammasomes and may serve as a potential therapeutic strategy for HN treatment.
- | Journal: Aloperine alleviates lipopolysaccharide-induced acute lung injury by inhibiting NLRP3 inflammasome activation. (Pubmed Central) - Jun 16, 2023
These findings suggest that CQ inhibits the activation of NLRP3 inflammasomes and may serve as a potential therapeutic strategy for HN treatment. Alo reduces NLRP3 inflammasome activation via the Nrf2 pathway in ALI mice.
- | Journal: Ergolide covalently binds NLRP3 and inhibits NLRP3 inflammasome-mediated pyroptosis. (Pubmed Central) - Jun 16, 2023
Our results revealed that the anti-pyroptosis effect of ERG are dependent on NLRP3 and NLRP3 NACHT domain is ERG's direct target. Therefore, ERG can serve as a precursor drug for the development of novel NLRP3 inhibitors to treat NLRP3 inflammasome mediated inflammatory diseases.
- | Journal: Is there a role for ketones as alternative fuel in critical illness? (Pubmed Central) - Jun 12, 2023
Therefore, ERG can serve as a precursor drug for the development of novel NLRP3 inhibitors to treat NLRP3 inflammasome mediated inflammatory diseases. Whilst ketones provide an attractive nutritional option, further research is required to determine whether the proposed benefits are translatable to critically unwell patients.
- | Journal: NLRP3 inflammasome-driven IL-1? and IL-18 contribute to lipopolysaccharide-induced septic cardiomyopathy. (Pubmed Central) - Jun 12, 2023
Our findings demonstrate that the cross-regulation of NLRP3 inflammasome-driven IL-1? and IL-18 contributes to the pathophysiology of SCM and provide new insights into the mechanism underlying the pathogenesis of SCM.
- | paclitaxel / Generic mfg.
Journal: Stat5 inhibits NLRP3-mediated pyroptosis to enhance chemoresistance of breast cancer cells via promoting miR-182 transcription. (Pubmed Central) - Jun 12, 2023
BC cell lines resistant to paclitaxel (PTX) and cis-diamminedichloro-platinum (DDP) were prepared...miR-182 inhibited NLRP3. Overall, Stat5 bound to the promoter region of miR-182 to promote miR-182 expression and inhibit NLRP3 transcription, thereby suppressing pyroptosis and enhancing CR of BC cells.
- | Journal: "Trichosanthis Fructus-Allii Macrostemonis Bulbus" combination inhibits NLRP3 inflammasome activation and reduces inflammatory response in RAW264.7 macrophage by inducing autophagy (Pubmed Central) - Jun 11, 2023
Furthermore, 3-methyladenine(3-MA) could reverse the inhibitory effect of GX on NLRP3, ASC, and caspase-1 and reduce the release of IL-18 and IL-1?. In summary, GX can increase of the autophagy activity of RAW264.7 and inhibit the activation of NLRP3 inflammasome, thereby reducing the release of inflammatory cytokines and suppressing inflammatory response in macrophages.
- The Effect of Neuroinflammation and Cell Death on the Electrophysiological Properties of Spikes and Local Field Potentials in the Ascending Visual Pathway of Danio rerio (Montreal Bonaventure Hotel (CAN meeting headquarters)) - Jun 10, 2023 - Abstract #CANACN2023CAN_ACN_464;
Further, MPTP treatment decreased the waveform variability. Both the LFP and spike analysis support a contribution of Panx1a to the modulation of neuronal networks under conditions of neuroinflammation.
- | Preclinical, Journal: Electroacupuncture at ST 36 ameliorates cognitive impairment and beta-amyloid pathology by inhibiting NLRP3 inflammasome activation in an Alzheimer's disease animal model. (Pubmed Central) - Jun 9, 2023
Both the LFP and spike analysis support a contribution of Panx1a to the modulation of neuronal networks under conditions of neuroinflammation. EA stimulation at ST 36 effectively improved memory impairment in 5
- | Preclinical, Journal: Syringic Acid Alleviates Dextran Sulfate Sodium-Induced Colitis in Mice by Modulating Gut Microbiota. (Pubmed Central) - Jun 8, 2023
inflammatory vesicle signaling pathway, leading to amelioration of colonic inflammation in a gut microbiota-dependent manner. Our findings demonstrate the potential of syringic acid as a preventive and therapeutic agent for inflammatory bowel disease.
- | Journal: Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-?B/NLRP3 Axis. (Pubmed Central) - Jun 5, 2023
NLRP3 inhibitor MCC950 can inhibit pyroptosis of podocytes exposed to high glucose. Altogether, our results demonstrate that the protective effect of AS-IV in upregulating klotho expression in diabetes-induced podocyte injury is associated with the inhibition of NLRP3-mediated pyroptosis via the NF-?B signaling pathway.
- | dexamethasone / Generic mfg.
Preclinical, Journal: Artesunate alleviates hypoxic-ischemic brain damage in neonatal rats by inhibiting NLRP3 inflammasome activation and inflammatory cytokine secretion (Pubmed Central) - Jun 3, 2023
Methods 7-day-old neonatal SD rats were randomly divided into sham operation group, model group, artesunate 5 mg/kg group, artesunate 10 mg/kg group, artesunate 20 mg/kg group and dexamethasone 6 mg/kg group, with 18 rats in each group...Conclusion Artesunate can improve the neurological function, relieve the brain damage, and alleviate the brain edema in neonatal rats with HIBD. It can protect the HIBD, which may be related to the inhibition of NLRP3 inflammasome activation and reduction of inflammatory cytokine secretion.
- | Journal: SIRT1 slows the progression of lupus nephritis by regulating the (Pubmed Central) - Jun 1, 2023
Our findings suggest that upregulated SIRT1 inhibits the NLRP3 inflammasome to slow the progression of lupus nephritis by regulating NF-?B and ROS/TRPM2/Ca channels. This study reveals a new anti-inflammatory mechanism of SIRT1, suggesting that SIRT1 may be a potential therapeutic target for the prevention of LN.
- | Journal: Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19. (Pubmed Central) - Jun 1, 2023
This study reveals a new anti-inflammatory mechanism of SIRT1, suggesting that SIRT1 may be a potential therapeutic target for the prevention of LN. Furthermore, the ORF8-induced inflammasome response was readily inhibited by the NLRP3 inhibitor MCC950 in
- | Preclinical, Journal: NLRP3 inflammasome inhibition and M1-to-M2 microglial polarization shifting via scoparone-inhibited TLR4 axis in ovariectomy/D-galactose Alzheimer's disease rat model. (Pubmed Central) - Jun 1, 2023
This was associated with repression of NLRP3 inflammasome along with M1-to-M2 microglia polarization shifting as exemplified by mitigating pro-inflammatory M1 marker (CD86) and elevating M2 neuroprotective marker (CD163). Therefore, SCO could promote microglia transition towards M2 through switching off TLR4/MyD88/TRAF-6/TAK-1/NF-?B axis and inhibiting NLRP3 pathway, with consequent mitigation of neuroinflammation and neurodegeneration in OVX/D-Gal AD model.
- | amiodarone / Generic mfg.
Preclinical, Journal: Suppressing NLRP3 activation and PI3K/AKT/mTOR signaling ameliorates amiodarone-induced pulmonary fibrosis in rats: a possible protective role of nobiletin. (Pubmed Central) - Jun 1, 2023
release, prohibited TGF-?1-related PI3K/AKT/mTOR cascade, suppressed ?-SMA expression, and impeded collagen deposition. These findings point to a novel strategy by which NOB may alleviate the AMD-prompted NLRP3 inflammatory responses and associated PF through blocking PI3K/AKT/mTOR signaling.
- | Journal: NLRP3 Disturbs Treg/Th17 Cell Balance to Aggravate Apical Periodontitis. (Pubmed Central) - Jun 1, 2023
Nigericin administration, however, exacerbated periapical inflammation and bone destruction with an unbalanced Treg/Th17 response. These findings demonstrate that NLRP3 is a pivotal regulator by regulating the release of inflammatory cytokines from DCs or directly suppressing Foxp3 expression to disturb Treg/Th17 balance, thus exacerbating apical periodontitis.
- | Journal: CVB3 Inhibits NLRP3 Inflammasome Activation by Suppressing NF-?B Pathway and ROS Production in LPS-Induced Macrophages. (Pubmed Central) - May 31, 2023
Collectively, our study revealed a novel mechanism of NLRP3 inflammasome activation by suppressing the NF-?B pathway and ROS production in LPS-induced macrophages. Our findings may provide new ideas for antiviral treatment and drug development for CVB3 infection.
- atazanavir / Generic mfg.
Atazanavir Causes Apoptosis Through Activateion of NLRP3 Inflammasome Pathway (Exhibit and Poster Hall (Hall BCD)) - May 31, 2023 - Abstract #ASMMicrobe2023ASM_Microbe_1893;
In conclusion, ATV cell death is through the NLRP3 inflammasome/pyroptosis pathway. Thus ATV-induced mitochondrial dysfunction may increase ROS production resulting in the activation of NLRP3 inflammasome pathway.
- Intracellular Invasion of Orientia tsutsugamushi Induces Cathepsin- and NLRP3-Dependent Inflammasome Activation, IL-1? Release and Cell Death in Human Monocyte-Derived Macrophages (Exhibit and Poster Hall (Hall BCD)) - May 31, 2023 - Abstract #ASMMicrobe2023ASM_Microbe_1298;
Cell death in OT-infected macrophages was mediated by cathepsin and NLRP3-dependent inflammasome activation resulting in caspase-1 activation, IL-1? release and cell death.
- | deoxyglucose / Generic mfg.
Journal: Recombinant Treponema pallidum Protein Tp47 Promoted the Phagocytosis of Macrophages by Activating NLRP3 Inflammasome Induced by PKM2-Dependent Glycolysis. (Pubmed Central) - May 29, 2023
release and cell death. Tp47 promotes phagocytosis in macrophages by activating the NLRP3 inflammasome, which is induced by the enhancement of PKM2-dependent glycolysis.
- | dimethylamino micheliolide (ACT001) / Tianjin Suntech Pharma
Journal: ACT001 Ameliorates ionizing radiation-induced lung injury by inhibiting NLRP3 inflammasome pathway. (Pubmed Central) - May 29, 2023
The results demonstrated that ACT001 ameliorated RILI, diminished pro-inflammatory cytokine release and fibrosis, and mitigated the activation of the NLRP3 inflammasome while inhibiting pyroptosis in lung tissue. In conclusion, our study reveals that ACT001 can suppress NLRP3 inflammasome-mediated pyroptosis and improve RILI, suggesting its potential as a novel protective agent for RILI.
- | piceatannol / New York Medical College, Kyushu University
Journal: Piceatannol protects against age-related hearing loss by inhibiting cellular pyroptosis and inflammation through regulated Caspase11-GSDMD pathway. (Pubmed Central) - May 29, 2023
In conclusion, these results suggest a protective role for PCT against ARHL, possibly through Caspase-11-GSDMD pathway. Our findings may provide a new target and theoretical basis for hearing loss treatment using PCT.
- | Journal: Abietane diterpenoids from Orthosiphon wulfenioides with NLRP3 inflammasome inhibitory activity. (Pubmed Central) - May 29, 2023
Our findings may provide a new target and theoretical basis for hearing loss treatment using PCT. Bioactivity screening indicated that compounds 1-4, 6 and 8 exhibited lactate dehydrogenase (LDH) inhibition effect with IC values ranging from 0.23 to 3.43
- | Journal: Targeting the NLRP3 inflammasome reduces inflammation in hidradenitis suppurativa skin. (Pubmed Central) - May 27, 2023
Bioactivity screening indicated that compounds 1-4, 6 and 8 exhibited lactate dehydrogenase (LDH) inhibition effect with IC values ranging from 0.23 to 3.43 These data provide a rationale for targeting the NLRP3 inflammasome in HS using small molecule inhibitors which are currently being tested for other indications.
- | Journal: HuNoV Non-Structural Protein P22 Induces Maturation of IL-1? and IL-18 and N-GSDMD-Dependent Pyroptosis through Activating NLRP3 Inflammasome. (Pubmed Central) - May 27, 2023
Besides, berberine (BBR) could ameliorate the pyroptosis caused by HuNoV and P22 by inhibiting NLRP3 inflammasome activation. Together, these results reveal new insights into the mechanisms of inflammation and cell death caused by HuNoV and provide potential treatments.
- | fluoxetine / Generic mfg.
Journal: Association between Fluoxetine Use and Overall Survival among Patients with Cancer Treated with PD-1/L1 Immunotherapy. (Pubmed Central) - May 27, 2023
This cohort study among cancer patients treated with checkpoint inhibitor therapy showed a significant improvement in the OS when fluoxetine was used. Because of this study's potential for selection bias, randomized trials are needed to assess the efficacy of the association of fluoxetine or another anti-NLRP3 drug to checkpoint inhibitor therapy.
- | Journal: Epimedium Aqueous Extract Ameliorates Cerebral Ischemia/Reperfusion Injury through Inhibiting ROS/NLRP3-Mediated Pyroptosis. (Pubmed Central) - May 27, 2023
Most interestingly, the main compounds of EP directly bonded with NLRP3, as reflected by molecular docking, which indicated that NLRP3 might be a promising therapeutic target for EP-elicited cerebral protection. In conclusion, our findings illustrate that ICS II protects against neuron loss and neuroinflammation after CIRI by inhibiting ROS/NLRP3-mediated pyroptosis.
- || Review, Journal: Natural products in attenuating renal inflammation via inhibiting the NLRP3 inflammasome in diabetic kidney disease. (Pubmed Central) - May 26, 2023
Research has demonstrated that many natural products can alleviate DKD by targeting the NLRP3 inflammasome. In this review, we highlight the role of the NLRP3 inflammasome in DKD, and the pathways by which natural products fight against DKD via inhibiting the NLRP3 inflammasome activation, so as to provide novel insights for the treatment of DKD.
- | Journal: A novel mechanism regulating pyroptosis-induced fibrosis in endometriosis via lnc-MALAT1/miR-141-3p/NLRP3 pathway. (Pubmed Central) - May 26, 2023
release, thereby relieving TGF-?1-mediated fibrosis. Consequently, our findings suggest that lnc-MALAT1 is critical for NLRP3-induced pyroptosis and fibrosis in endometriosis through sponging miR-141-3p, which may indicate a new therapeutic target of endometriosis treatment.